Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

@article{Dekelver2013AttenuationOA,
  title={Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.},
  author={Russell Dekelver and Ming Yan and Eun-young Ahn and Wei-Jong Shia and Nancy A. Speck and Dong-Er Zhang},
  journal={Blood},
  year={2013},
  volume={121 18},
  pages={
          3714-7
        }
}
AML1-ETO (RUNX1-ETO) fusion proteins are generated by the 8;21 translocation, commonly found in acute myeloid leukemia, which fuses the AML1 (RUNX1) and ETO (MTG8, RUNX1T1) genes. Previous studies have shown that AML1-ETO interferes with AML1 function but requires additional cooperating mutations to induce leukemia development. In mouse models, AML1-ETO forms lacking the C-terminus have been shown to have greatly enhanced leukemogenic potential. Here, we investigate the role of 2 AML1-ETO C… Expand
TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.
TLDR
It is shown that the loss of TLE4 confers proliferative advantage to leukemic cells, simultaneous with an upregulation of a pro- inflammatory signature mediated through aberrant increases in Wnt signaling activity, pointing towards a novel therapeutic approach for myeloid leukemia. Expand
Cooperation between RUNX1-ETO9a and Novel Transcriptional Partner KLF6 in Upregulation of Alox5 in Acute Myeloid Leukemia
TLDR
RUNX1-ETO9a, the leukemogenic alternatively spliced transcript expressed from t(8;21), upregulates target gene Alox5, which is a gene critically required for the promotion of chronic myeloid leukemia development by BCR-ABL, a protein required for early hematopoiesis and yolk sac development. Expand
Cooperation between RUNX 1-ETO 9 a and Novel Transcriptional Partner KLF 6 in Upregulation of Alox 5 in Acute Myeloid Leukemia
Fusion protein RUNX1-ETO (AML1-ETO, RUNX1-RUNX1T1) is expressed as the result of the 8q22;21q22 translocation [t(8;21)], which is one of the most common chromosomal abnormalities found in acuteExpand
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
Oncogenic fusion protein RUNX1-ETO is the product of the t(8;21) translocation, responsible for the most common cytogenetic subtype of acute myeloid leukemia. RUNX1, a critical transcription factorExpand
Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
TLDR
It is reported here that wild-type AML1 is able to orchestrate the expression of AML 1/ETO targets regardless of being activated or repressed; this is achieved via forming a complex with AMl1/ETo and via recruiting the cofactor AP-1 on chromatin. Expand
Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation
TLDR
It is demonstrated that increased oncogene dosage is a critical parameter of AE9a transformation, likely as a result of impaired transcriptional regulation of AML1-ETO target genes, and this insight could assist in identifying those downstream genes most critical for t(8;21)-associated transformation. Expand
Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion
TLDR
It is shown that the NHR2 and NHR4 domain structures do not have irreplaceable functions concerning RUNX1/ETO activity for the establishment of human CD34+ cell expansion, and can be replaced by heterologous protein domains conferring tetramerization and repressor functions. Expand
JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.
TLDR
It is demonstrated that the histone demethylase JMJD1C functions as a coactivator for RUNX1-RUNX1T1 and is required for its transcriptional program and shows a critical role in the survival of multiple human AML cell lines. Expand
RUNX1–ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development
TLDR
It is reported here that interferons (IFNs) and IFN-stimulated genes are a group of genes consistently up-regulated by RUNX1–ETO in both human and murine models and supports the use of type I IFNs in the treatment of AML. Expand
Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
  • Juan Zhang, Xuefeng Gao, Li Yu
  • Medicine
  • Frontiers in Oncology
  • 2021
Accurate orchestration of gene expression is critical for the process of normal hematopoiesis, and dysregulation is closely associated with leukemogenesis. Epigenetic aberration is one of the majorExpand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
TLDR
Observations suggest a previously uncharacterized mechanism of tumorigenesis, in which secondary mutation(s) in molecular events disrupting the function of a domain of the oncogene promote the development of malignancy. Expand
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis
TLDR
The crucial role of the NHR4 domain in determination of cellular fate during AML1-ETO-associated leukemogenesis is uncovered and identified SON, a DNA/RNA-binding domain containing protein, as a novel NHR3/NHR4-interacting protein. Expand
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.
TLDR
The results demonstrate that AML1-ETO has a very restricted capacity to transform cells and will be necessary to develop a model for studying the pathogenesis of t(8;21) leukemia. Expand
The 8;21 translocation in leukemogenesis
TLDR
Structural aspects of the fusion protein and the accumulated knowledge from in vitro analyses on AML1-ETO functions are discussed, and putative mechanisms of its leukemogenic potential are outlined. Expand
Analysis of the role of AML 1-ETO in leukemogenesis , using an inducible transgenic mouse model
As reported previously, AML1-ETO knock-in mice were generated to investigate the role of AML1-ETO in leukemogenesis and to mimic the progression of t(8;21) leukemia. These knock-in mice died inExpand
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
TLDR
It is found that ETO, through its interaction with the N-CoR/mSin3/HDAC1 complex, is also a potent repressor of transcription, providing a mechanism for how the AML1/ETO fusion may inhibit expression of AML 1-responsive target genes and disturb normal hematopoiesis. Expand
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis
TLDR
The identification of a previously unknown alternatively spliced isoform of the AML1-ETO transcript that includes an extra exon, exon 9a, of the ETO gene is reported, indicating that fusion proteins from alternativelyspliced isoforms of a chromosomal translocation may work together to induce cancer development. Expand
Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO
TLDR
It is reported that ETO, which is fused to the acute myelogenous leukemia 1 (AML1) transcription factor in t(8;21) AML, interacts via its zinc finger region with a conserved domain of the corepressors N-CoR and SMRT and recruits HDAC in vivo. Expand
ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors
TLDR
It is demonstrated that ETO interacts with the nuclear receptor corepressor N-CoR, the mSin3 corepressors, and histone deacetylases, suggesting that it is a component of one or more core pressor complexes. Expand
Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
TLDR
A concise review on complementing mutations in CBF leukemias including pathophysiology, mouse models, and clinical implications is presented. Expand
...
1
2
3
...